Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat

[1]  R. Hauer,et al.  Outcome in Phospholamban R14del Carriers: Results of a Large Multicentre Cohort Study , 2014, Circulation. Cardiovascular genetics.

[2]  H. Duff,et al.  Phospholamban Knockout Breaks Arrhythmogenic Ca2+ Waves and Suppresses Catecholaminergic Polymorphic Ventricular Tachycardia in Mice , 2013, Circulation research.

[3]  D. Kučerová,et al.  Enalaprilat increases PPARβ/δ expression, without influence on PPARα and PPARγ, and modulate cardiac function in sub-acute model of daunorubicin-induced cardiomyopathy. , 2013, European journal of pharmacology.

[4]  M. Bonini,et al.  Mitochondria Oxidative Stress, Connexin43 Remodeling, and Sudden Arrhythmic Death , 2013, Circulation. Arrhythmia and electrophysiology.

[5]  P. Krenek,et al.  Discrepant Regulation of QT (QTc) Interval Duration by Calcium Channel Blockade and Angiotensin Converting Enzyme Inhibition in Experimental Hypertension , 2012, Basic & clinical pharmacology & toxicology.

[6]  I. Sjaastad,et al.  ACE inhibition prevents diastolic Ca2+ overload and loss of myofilament Ca2+ sensitivity after myocardial infarction. , 2012, Current molecular medicine.

[7]  Jianming Xu,et al.  Interaction between the Cardiac Rapidly (IKr) and Slowly (IKs) Activating Delayed Rectifier Potassium Channels Revealed by Low K+-induced hERG Endocytic Degradation* , 2011, The Journal of Biological Chemistry.

[8]  D. Kučerová,et al.  Enalapril decreases cardiac mass and fetal gene expression without affecting the expression of endothelin-1, transforming growth factor β-1, or cardiotrophin-1 in the healthy normotensive rat. , 2011, Canadian journal of physiology and pharmacology.

[9]  J. Klimas,et al.  Heart rate correction of the QT duration in rats. , 2010, European journal of pharmacology.

[10]  Roger J Hajjar,et al.  Targeted SERCA2a Gene Expression Identifies Molecular Mechanism and Therapeutic Target for Arrhythmogenic Cardiac Alternans , 2009, Circulation. Arrhythmia and electrophysiology.

[11]  B. Knollmann,et al.  Cardiac Calsequestrin: The New Kid on the Block in Arrhythmias , 2009, Journal of cardiovascular electrophysiology.

[12]  D. Kučerová,et al.  Isoproterenol‐induced heart failure in the rat is associated with nitric oxide‐dependent functional alterations of cardiac function , 2009, European journal of heart failure.

[13]  L. Bachárová,et al.  Discrepancy between increased left ventricular mass and "normal" QRS voltage is associated with decreased connexin 43 expression in early stage of left ventricular hypertrophy in spontaneously hypertensive rats. , 2008, Journal of electrocardiology.

[14]  P. Ellinor,et al.  Prevention of Ventricular Arrhythmias With Sarcoplasmic Reticulum Ca2+ ATPase Pump Overexpression in a Porcine Model of Ischemia Reperfusion , 2008, Circulation.

[15]  C. Shi,et al.  Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor , 2008, British journal of pharmacology.

[16]  P. Švec,et al.  The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo. , 2007, European journal of pharmacology.

[17]  Michael D. Schneider,et al.  Cardiomyocyte‐specific inactivation of transcription factor CREB in mice , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  D. Bers,et al.  Regulation of Ca2+ and Na+ in Normal and Failing Cardiac Myocytes , 2006, Annals of the New York Academy of Sciences.

[19]  A. Alsheikh-Ali,et al.  The Renin‐Angiotensin System: A Therapeutic Target in Atrial Fibrillation , 2006, Pacing and clinical electrophysiology : PACE.

[20]  J. Narula,et al.  Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias. , 2006, The American journal of cardiology.

[21]  G. Dorn,et al.  A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Michael J. Wilson,et al.  Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. , 2004, Heart rhythm.

[23]  G. Fishman,et al.  Modulation of Cardiac Gap Junction Expression and Arrhythmic Susceptibility , 2004, Circulation research.

[24]  U Ravens,et al.  L-Type Ca 2 Current Downregulation in Chronic Human Atrial Fibrillation Is Associated With Increased Activity of Protein Phosphatases , 2004 .

[25]  J. Guerrero,et al.  Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Wen-Chung Yu,et al.  Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. , 2003, European heart journal.

[27]  G. Hindricks,et al.  Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. , 2003, Journal of the American College of Cardiology.

[28]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[29]  A. Ducharme,et al.  Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) Trials , 2003, Circulation.

[30]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[31]  E. Bernal,et al.  Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study , 2002, Circulation.

[32]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[33]  W. Schmitz,et al.  Enhanced protein phosphorylation in hypertensive hypertrophy. , 2001, Cardiovascular research.

[34]  A. Goette,et al.  Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. , 2000, Circulation.

[35]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[36]  D. Burkhoff,et al.  PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor) Defective Regulation in Failing Hearts , 2000, Cell.

[37]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[38]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[39]  L. Køber,et al.  Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. , 1999, Circulation.

[40]  G. Hasenfuss,et al.  Alterations of calcium-regulatory proteins in heart failure. , 1998, Cardiovascular research.

[41]  M. Diaz,et al.  Enhanced Ca2+ current and decreased Ca2+ efflux restore sarcoplasmic reticulum Ca2+ content after depletion. , 1997, Circulation research.

[42]  Y. Pinto,et al.  Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca2+‐ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy , 1997, Journal of hypertension.

[43]  H. Rockman,et al.  Overexpression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. , 1997, The Journal of clinical investigation.

[44]  A. Davidoff,et al.  Expression of calcium channels in adult cardiac myocytes is regulated by calcium. , 1997, Journal of molecular and cellular cardiology.

[45]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[46]  D. Chemla,et al.  Sarcoplasmic reticulum Ca2+ pumps in heart and diaphragm of cardiomyopathic hamster: effects of perindopril. , 1995, American Journal of Physiology.

[47]  P. Erne,et al.  Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. , 1994, The Journal of clinical investigation.

[48]  L. Jones,et al.  Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to beta-adrenergic stimulation. , 1989, The Journal of biological chemistry.

[49]  M. Curtis,et al.  Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia. , 1988, Cardiovascular research.

[50]  R. Campbell,et al.  The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. , 1988, Cardiovascular research.

[51]  A. Waldo.  Angiotensin II Receptor Blockade Reduces New-Onset Atrial Fibrillation and Subsequent Stroke Compared to Atenolol: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study , 2006 .

[52]  Y. Takeishi,et al.  Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure. , 1999, American journal of physiology. Heart and circulatory physiology.

[53]  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.